A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
News
Researchers and clinicians are gathering in San Diego and online for the 11th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, a three-day meeting focused on multiple sclerosis (MS) research and care. ACTRIMS 2026, being held Feb. 5-7 at the Marriott Marquis San Diego…
A new study suggests that how certain immune cells respond to Mavenclad (cladribine) may help explain why the treatment works well for some people with multiple sclerosis (MS), but less so for others. The researchers found that regulatory T-cells, or Tregs — immune cells…
Teva Canada and Novartis Canada formed a partnership to ensure continued access to Mayzent (siponimod) for people in Canada living with active secondary progressive multiple sclerosis (SPMS). Teva Canada will take over the promotion, distribution, and commercialization of the oral MS therapy in Canada. The companies say…
Experimental Bruton’s tyrosine kinase (BTK) inhibitors, such as tolebrutinib or evobrutinib, are as effective as the approved therapy Aubagio (teriflunomide) at preventing relapses in people with relapsing forms of multiple sclerosis (MS), according to a review of published studies. The review found the therapies to be…
Years before a diagnosis of multiple sclerosis (MS), people who later develop the disease have more doctor visits and hospitalizations for sensory, nervous system, and muscle problems than people in the general population, according to a recent study. The findings support the idea of an early phase of MS,…
Closely following a Mediterranean diet — which involves eating lots of fruits, vegetables, and whole grains, and limiting intake of processed and sugary foods — is associated with a significantly lower risk of developing multiple sclerosis (MS), a large Swedish study has found. The benefits, however, were seen mostly…
For people with multiple sclerosis (MS), difficulty walking is not just about physical limitations. It is also shaped by emotions, social interactions, and how easily people can take part in everyday life, a review study found. The findings highlight the many factors that can negatively affect walking in MS,…
A brief, four-session stress management program created by the Cleveland Clinic is helping people with multiple sclerosis (MS) significantly reduce their depression and anxiety. By using real-time biofeedback and mindfulness, the streamlined protocol offers patients a practical way to reclaim some control over their emotional and physical health without…
People with multiple sclerosis (MS) reported improvements in physical and mental quality of life along with reduced depression after one year of treatment with an ocrelizumab biosimilar, according to a small study conducted in Iran. The observational study followed 30 adults with MS who received Xacrel, an ocrelizumab biosimilar…
Older adults with multiple sclerosis (MS) show a higher prevalence and severity of cognitive impairment — particularly affecting information processing speed and memory — than younger patients, a new study reports. However, age was not directly associated with cognitive impairment, the results showed. Instead, greater disability emerged as the…
Oligodendrocytes, the cells responsible for making myelin, are constantly being made throughout the brain and spinal cord, even when there’s no myelin damage, according to a new study by U.S. researchers. These findings challenge the long-held view that oligodendrocyte precursor cells mostly differentiate into oligodendrocytes at sites of damage…
Taking part in a six-week yoga program improved self-reported physical activity and sleep quality, and reduced fatigue among people with multiple sclerosis (MS), according to a new study from Turkey. In a randomized clinical trial (NCT06128668), researchers assessed the benefits of yoga sessions, compared to no intervention,…
AB Science has received a patent in Japan covering the use of its investigational oral therapy masitinib for progressive forms of multiple sclerosis (MS). The new patent — JP 7788154 — grants the France-based pharmaceutical company protection in the Asian nation through February 2041 on the use of masitinib…
Treatment with the nasal spray therapy foralumab stabilized disability over six months in all 10 people with nonactive secondary progressive multiple sclerosis (SPMS) who took part in an expanded access program, according to a peer review. For those who received treatment for at least one year, the majority experienced…
Bionxt Solutions’ experimental sublingual therapy BNT23001 led to about 40% higher blood exposure to cladribine than a conventional oral tablet formulation, such as those used in multiple sclerosis (MS) therapies like Mavenclad, the company reported. The results come from a preclinical study in adult miniature pigs,…
When immune B-cells mistakenly recognize the body’s own nerve tissue, they can shut themselves down to prevent damage, but infection with the Epstein-Barr virus (EBV) can trick B-cells into surviving and becoming activated in the brain instead of being eliminated by normal immune safety mechanisms, according to a study.
Hyperfine’s Swoop system, the first U.S. Food and Drug Administration (FDA)-cleared AI-powered portable MRI system for the brain, showed strong diagnostic agreement with conventional MRI scans and was preferred by patients, according to new study results. Because Swoop can be used in neurology clinics, it may help make…
People whose biological mothers had diabetes during pregnancy are more likely to develop multiple sclerosis (MS) as adults, according to a new study from Norway. The study also found that MS risk is heightened among people who were born unusually large, while babies who were abnormally small at birth…
Brenig Therapeutics has launched an early Phase 1 clinical trial to evaluate its experimental small molecule BT-409Â in healthy volunteers. The therapy is being developed for people with multiple sclerosis (MS) and other chronic neurologic conditions. It is aimed at blocking inflammatory responses by targeting the NLRP3 inflammasome,…
Taking oral caffeine supplements may significantly reduce fatigue and improve quality of life and mood in people with multiple sclerosis (MS), according to a recent clinical trial in Iran. Participants took 100 mg of caffeine tablets daily for 12 weeks, equivalent to about two shots of espresso, or a…
A brain protein called anoctamin-2 (ANO2) has emerged as a new piece of the puzzle linking Epstein-Barr virus (EBV) infections to multiple sclerosis (MS), according to a study. Researchers found that immune T-cells from people with MS can mistake ANO2 for an EBV protein, triggering a cross-reactive response…
A new machine learning tool can now help predict whether people newly diagnosed with multiple sclerosis (MS) will experience disability worsening that occurs even in the absence of relapses. According to a recent study, these artificial intelligence algorithms can identify the risk of “progression independent of relapse activity,” or…
Paralyzed Veterans of America (PVA) — a congressionally chartered veterans organization open to all military service members with multiple sclerosis (MS) — has launched a new, free, online fitness and wellness program that offers adaptive, expert-led classes for individuals with mobility challenges. The initiative is designed specifically…
A history of the Epstein-Barr virus (EBV) appears to alter the immune systems of people with specific genetic traits, causing their own cells to mistakenly flag brain proteins as dangerous threats, according to a new study. This discovery offers insight into how these risk factors — viral infection and…
A greater intake of vitamin D, from both food and supplements, was linked to a 42% lower risk of developing multiple sclerosis (MS) among women living in Norway, according to a large prospective study. “Our findings suggest that a higher dietary intake of vitamin D decreases the risk of…
Find Therapeutics has secured CA$10 million (approximately $7.4 million) in funding to continue advancing tasronetide, its lead candidate for boosting myelin repair in people with multiple sclerosis (MS). The Series A extension financing round follows the completion of a Phase 1 trial in healthy volunteers, in which tasronetide…
People with multiple sclerosis (MS) who have mild disability still experience several disease-related difficulties at work — challenges that can lead employees to shift to part-time or possibly quit their jobs — even after their condition is disclosed, a new study in Norway highlights. In particular, there are three…
A group of international experts has proposed a first-of-its-kind framework aimed at preventing multiple sclerosis (MS) from developing. Rather than focusing on a single cause, the framework outlines multiple opportunities to lower MS risk across a person’s life, from reducing childhood obesity and viral exposures to addressing smoking and…
Evogene and Unravel Biosciences are collaborating to develop a new class of therapies targeting myelin repair in multiple sclerosis (MS) and similar disorders. By combining two distinct artificial intelligence platforms, the companies hope to create the first treatment capable of…